Dec 11, 2024
top of page
JNJ/PTGX: Icotrokinra ANTHEM-Ulercative Colitis efficacy similar to oral competitors
Mar 10, 2025
Despite headline efficacy in PTGX/JNJ's ulcerative colitis phase 2 ANTHEM-UC at its highest dose, the initial efficacy appears similar to that of already FDA-approved orals and other oral classes in development. With limited safety and patient characteristic disclosure...
bottom of page